MYD88 and breast carcinoma: The induction of breast cancer cell lines (MDA-MB-231 and T47D) with the TLR3 ligand induces cellular proliferation through an MyD88-dependent manner via induction of proinflammatory cytokine IL-6 and cyclin D1.